BRCA1 and BRCA2 tumours have different responses to immune checkpoint blockade

Mutations in BRCA2 but not BRCA1 are associated with  tumours that respond well to immunotherapy, a US study has found. In a surprising finding that has overturned assumptions about tumour responses to immunotherapy, researchers at Memorial Sloan Kettering Cancer Centre, New York, found divergent effects of BRCA1 and BRCA2 deficiency on the tumour microenvironment and ...